CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5626-5634

  Haining, W Nicholas ^a,b   Davies, Jeffrey ^b   Kanzler, Holger ^e   Drury, Linda ^b   Brenn, Thomas ^d   Evans, John ^b   Angelosanto, Jill ^b   Rivoli, Steven ^b   Russell, Kate ^b   George, Suzanne ^b   Sims, Paul ^e   Neuberg, Donna ^c   Li, Xiaochun ^c   Kutok, Jeffrey ^d   Morgan, Jeffrey ^b   Wen, Patrick ^b   Demetri, George ^b   Coffman, Robert L ^e   Nadler, Lee M ^b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b Department of Pediatric Oncology ^*  (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Dynavax Technologies Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ISOLEUCYLLEUCYLALANYLLYSYLPHENYLALANYLLEUCYLHISTIDYLTRYPTOPHANYLLEUCINE; ISOLEUCYLLEUCYLLYSYLGLUTAMYLPROLYLVALYLHISTIDYLGLYCYLVALINE; PEPTIDE VACCINE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; CANCER VACCINE; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; SUBUNIT VACCINE; TELOMERASE; TERT PROTEIN, HUMAN; TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 9;

ABDOMINAL PAIN; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BONE PAIN; BRAIN TUMOR; CD8+ T LYMPHOCYTE; CELL MIGRATION; CELLULAR IMMUNITY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DENDRITIC CELL; DESQUAMATION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; FEVER; FLUSHING; HEADACHE; HEARTBURN; HOT FLUSH; HUMAN; HYPERNATREMIA; HYPERSENSITIVITY; IMMUNOSTIMULATION; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; INSOMNIA; JAW PAIN; LEUKOPENIA; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RIGOR; SIDE EFFECT; SWEATING; THORAX PAIN; TREATMENT RESPONSE; URTICARIA; VISUAL DISORDER; CELL MOTION; DRUG ANTAGONISM; IMMUNOLOGY; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; CELL MOVEMENT; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES; TELOMERASE; TOLL-LIKE RECEPTOR 9; VACCINES, SUBUNIT;

EID: 53049085554     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0526     Document Type: Article

References (50)

1. Krieg A. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184-94.
2. Kanzler H, Barrat F, Hessel E, Coffman R. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13:552-9.
3. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306.
4. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U SA1997;94:10833-7.
5. Liu H,Newbrough S, Bhatia S, Dahle C, Krieg A, Weiner G. Immunostimulatory CpG oligodeoxy-nucleotides enhance the immune response to vaccine strategies involving granulocyte-macro-phage colony-stimulating factor. Blood 1998;92: 3730-6.
6. Davila E, Celis E. Repeated administration of cyto-sine- phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 2000;165:539-47.
7. Miconnet I, Koenig S, Speiser D, et al. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 2002;168:1212-8.
8. Davila E, Kennedy R, Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxy nucleotide adjuvant, and CTLA-4 blockade. Cancer Res 2003;63:3281-8.
9. + T cell responses. J Immunol 2006;177:8860-73.
10. + T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides. Clin Immunol 2007;124:119-30.
11. Sandler A, Chihara H, Kobayashi G, et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 2003;63:394-9.
12. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115:739-46.
13. Valmori D, Souleimanian N,ToselloV, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA2007;104:8947-52.
14. Lonsdorf A, Kuekrek H, Stern B, BoehmB, Lehmann P,Tary-Lehmann M. Intratumor CpG-oligodeoxynucleo-tide injection induces protective antitumor Tce immunity. J Immunol 2003;171:3941-6.
15. Heckelsmiller K, Rall K, Beck S, et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002; 169:3892-9.
16. Kunikata N, Sano K, Honda M, et al. Peritumoral CpG oligodeoxynucleotide treatment inhibits tumor growth and metastasis of B16F10 melanoma cells. J Invest Dermatol 2004;123:395-402.
17. Furumoto K, Soares L, Engleman E, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 2004;113: 774-83.
18. Jakob T, Walker P, Krieg A, Udey M,Vogel J. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation ofTh1 responses by immunostimulatory DNA. J Immunol 1998;161:3042-9.
19. Li J, Song W, Czerwinski DK, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requiresTLR9 either in the host or in the tumor itself. J Immunol 2007;179:2493-500.
20. Krug A, Uppaluri R, Facchetti F, et al. IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation. J Immunol 2002;169:6079-83.
21. Penna G,Vulcano M, Roncari A, Facchetti F, Sozzani S, Adorini L. Cutting edge: differential chemokine production by myeloid and plasmacytoid dendritic cells. J Immunol 2002;169:6673-6.
22. Megjugorac N, Young H, Amrute S, Olshalsky S, Fitzgerald-Bocarsly P. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. J Leukoc Biol 2004;75: 504-14.
23. Decalf J, Fernandes S, Longman R, et al. Plasmacy-toid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target inchronic HCV patients. J Exp Med2007;204:2423-37.
24. Rot A, von Andrian U. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004;22:891-928
25. Castellino F, Huang A, Altan-Bonnet G, Stoll S, Scheinecker C, Germain R. Chemokines enhance immunity by guiding naive CD8(+) Tcells to sites of CD4 Tcell-dendritic cell interaction. Nature 2006;440:890-5.
26. Vonderheide R, Hahn W, Schultze J, Nadler L. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity1999;10:673-9.
27. van der Burg S, Klein M, van de Velde C, Kast W, Miedema F, Melief C. Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase. AIDS1995;9:121-7.
28. Macdonald D, Cascino T, Schold S, Cairncross J. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
29. Vonderheide R, Schultze J, Anderson K, et al. Equivalent induction of telomerase-specific cytotoxic Tlymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001;61:8366-70.
30. + T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol 1999;162:1780-8.
31. Mac Donald K, Munster D, Clark G, Dzionek A, Schmitz J, Hart D. Characterization of human blood dendritic cell subsets. Blood 2002;100:4512-20.
32. Vuckovic S, Gardiner D, Field K, et al. Monitoring dendritic cells in clinical practice using a new whole blood single-platform Tru COUNT assay. J Immunol Methods 2004;284:73-87.
33. Roers A, Hochkeppel H, Horisberger M, Hovanes-sian A, Haller O. MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis1994;169:807-13.
34. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen F. Plasmacytoid dendritic cells (natural in-terferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001;159:237-43.
35. Friedberg JW, Kim H, McCauley M, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non- Hodgkin lymphoma: increased interferon-α/β-inducible gene expression, without significant toxicity. Blood 2005;105:489-95.
36. Lipford GB, Sparwasser T, Zimmermann S, Heeg K, Wagner H. CpG-DNA-mediated transient lymphade-nopathy is associated with a state ofTh1 predisposition to antigen-driven responses. J Immunol 2000;165:1228-35.
37. Hartmann G,Weiner G, Krieg A. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A 1999;96: 9305-10.
38. Krieg A, Efler S, Wittpoth M, Al Adhami M, Davis H. Induction of systemicTH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotideTLR9 agonist. J Immunother 2004;27:460-71.
39. Wollenberg A, Wagner M, Gunther S, et al. Plasma-cytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002;119:1096-102.
40. Molenkamp BG, van Leeuwen PA, Meijer S, et al. Intradermal CpG-B activates both plasmacy-toid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 2007;13:2961-9.
41. Pashenkov M, Goess G,WagnerC, et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006;24:5716-24.
42. Bui J, Schreiber R. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 2007;19:203-8.
43. Clemente C, Mihm M, Bufalino R, Zurrida S, Col-lini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-10.
44. Zhang L, Conejo-Garcia J, Katsaros D, et al. Intra-tumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
45. +/regu-latoryT cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A2005;102:18538-43.
46. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
47. Fisher D, Chen Q, Appenheimer M, et al. Hurdles to lymphocyte trafficking in the tumor microenviron-ment: implications for effective immunotherapy. Immunol Invest 2006;35:251-77.
48. + T cells in the circulation but not in the tumor site. J Immunol 2006;177:1670-8.
49. Domchek SM, Recio A, Mick R, et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res 2007;67:10546-55.
50. + T lymphocytes. Clin Cancer Res 2004;10:828-39.